Baxter International Inc. (BAX) shares tumbled 7.00% in pre-market trading on Thursday following the release of its third-quarter earnings report, which presented a mixed picture and included lowered full-year guidance.

The medical products company reported adjusted earnings per share of $0.69, surpassing the analyst estimate of $0.60. However, revenue fell short of expectations, coming in at $2.835 billion compared to the estimated $2.875 billion. The company also reported a net loss of $46 million for the quarter, translating to an EPS of -$0.10.

Investors appear to be reacting negatively to Baxter's forward-looking statements. The company revised its full-year revenue growth forecast to 4-5%, down from previous estimates. Additionally, Baxter lowered its full-year adjusted EPS guidance to a range of $2.35-$2.40. For the fourth quarter, the company projects revenue growth of 2% and adjusted EPS between $0.52 and $0.57, which may be lower than what analysts were anticipating. This conservative outlook, combined with the revenue miss, seems to be driving the significant pre-market sell-off.